Form 4: Pasithea Therapeutics Director Acquires Stock Options

Director Simon Dumesnil acquired stock options in Pasithea Therapeutics Corp. on March 1, 2024, according to a Form 4 filing.

Summary

• On March 1, 2024, Simon Dumesnil, a director of Pasithea Therapeutics Corp. (KTTA), acquired stock options.
• The stock options grant the right to buy 7,500 shares of common stock at an exercise price of $8.34.
• The options vest in three annual installments of 33%, starting on the one-year anniversary of the grant date, provided Dumesnil remains a director.
• The options expire on February 28, 2034.
• The filing also notes a 1-for-20 reverse stock split that Pasithea Therapeutics Corp. effected on January 2, 2024, which adjusted the share amounts and exercise prices of outstanding equity awards.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a standard disclosure of stock option grants to a company director.

Future Outlook

The director's continued holding of the options is contingent on remaining a director of the company through the vesting dates.

Industry Context

This is a standard disclosure related to executive compensation and insider transactions, common in the biotech industry.

Stakeholder Impact

• The transaction could have a minor impact on shareholders by potentially diluting equity if the options are exercised in the future.

Key Dates

Keywords

stock options, Form 4, director, KTTA, Pasithea Therapeutics, beneficial ownership, reverse stock split